Numerous preclinical and clinical studies have shown the efficacy of anti-CD19 and anti-BCMA CAR-T cells in treating a range of autoimmune diseases, including SLE, by targeting CD19 + B cells or BCMA + plasma cells or double-positive plasmablasts (32, 33)
Bioavailability studies show significantly higher relative bioavailability compared with regular GSH, with a longer time to peak plasma concentration and a longer duration of action
While the move still needs the final stamp of approval from the FDA, placing these peptides in that less restricted category will allow compounders to create and sell these medications before their safety and effectiveness has been proven
Even experienced copper peptide users benefit from introducing 4% products slowly, perhaps every other day initially, then building to daily use as skin demonstrates consistent positive response without signs of irritation or sensitivity
A federal recommendation should never be interpreted as a personal treatment recommendation